# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Serge Belanger reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and maintains $40 price target.
Truist Securities analyst Les Sulewski maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and raises the price targ...
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate...
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...